JP6703806B2 - 低抗凝固剤ヘパリン - Google Patents
低抗凝固剤ヘパリン Download PDFInfo
- Publication number
- JP6703806B2 JP6703806B2 JP2014547145A JP2014547145A JP6703806B2 JP 6703806 B2 JP6703806 B2 JP 6703806B2 JP 2014547145 A JP2014547145 A JP 2014547145A JP 2014547145 A JP2014547145 A JP 2014547145A JP 6703806 B2 JP6703806 B2 JP 6703806B2
- Authority
- JP
- Japan
- Prior art keywords
- chemically modified
- heparin
- modified heparin
- molecular weight
- kda
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 title claims description 191
- 229920000669 heparin Polymers 0.000 title claims description 99
- 229960002897 heparin Drugs 0.000 title claims description 88
- 239000003146 anticoagulant agent Substances 0.000 title description 6
- 229940127219 anticoagulant drug Drugs 0.000 title description 6
- 238000000034 method Methods 0.000 claims description 97
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 69
- 150000004676 glycans Polymers 0.000 claims description 47
- 150000004804 polysaccharides Polymers 0.000 claims description 40
- 230000000694 effects Effects 0.000 claims description 31
- 201000004792 malaria Diseases 0.000 claims description 27
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 23
- 230000002829 reductive effect Effects 0.000 claims description 19
- 150000002016 disaccharides Chemical group 0.000 claims description 18
- 239000007800 oxidant agent Substances 0.000 claims description 18
- 239000004019 antithrombin Substances 0.000 claims description 17
- 230000009467 reduction Effects 0.000 claims description 17
- 230000001590 oxidative effect Effects 0.000 claims description 16
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 15
- 230000002429 anti-coagulating effect Effects 0.000 claims description 12
- 230000007062 hydrolysis Effects 0.000 claims description 11
- 238000006460 hydrolysis reaction Methods 0.000 claims description 11
- IAJILQKETJEXLJ-LECHCGJUSA-N iduronic acid Chemical group O=C[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-LECHCGJUSA-N 0.000 claims description 11
- 235000000346 sugar Nutrition 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- -1 periodate compound Chemical class 0.000 claims description 7
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical group O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 claims description 6
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 claims description 6
- 229960005385 proguanil Drugs 0.000 claims description 6
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 claims description 6
- 238000007385 chemical modification Methods 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 5
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims description 5
- 230000002378 acidificating effect Effects 0.000 claims description 4
- FIHJKUPKCHIPAT-AHIGJZGOSA-N artesunate Chemical group C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@@H](OC(=O)CCC(O)=O)[C@@H]4C FIHJKUPKCHIPAT-AHIGJZGOSA-N 0.000 claims description 2
- 229960004991 artesunate Drugs 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 62
- 230000008569 process Effects 0.000 description 53
- 241000700159 Rattus Species 0.000 description 24
- 210000003743 erythrocyte Anatomy 0.000 description 23
- 239000000047 product Substances 0.000 description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
- 244000045947 parasite Species 0.000 description 19
- 230000014508 negative regulation of coagulation Effects 0.000 description 17
- 239000002253 acid Substances 0.000 description 16
- 238000003756 stirring Methods 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 238000007254 oxidation reaction Methods 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 208000032843 Hemorrhage Diseases 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 11
- 230000000740 bleeding effect Effects 0.000 description 11
- 230000000875 corresponding effect Effects 0.000 description 11
- 238000009826 distribution Methods 0.000 description 11
- 230000003647 oxidation Effects 0.000 description 11
- 238000001556 precipitation Methods 0.000 description 11
- 210000003936 merozoite Anatomy 0.000 description 10
- 239000008213 purified water Substances 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- 210000003812 trophozoite Anatomy 0.000 description 10
- 230000021164 cell adhesion Effects 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 230000007193 modulation by symbiont of host erythrocyte aggregation Effects 0.000 description 9
- 238000009472 formulation Methods 0.000 description 8
- 230000035484 reaction time Effects 0.000 description 8
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 208000030852 Parasitic disease Diseases 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 231100000673 dose–response relationship Toxicity 0.000 description 7
- 229920001282 polysaccharide Polymers 0.000 description 7
- 239000005017 polysaccharide Substances 0.000 description 7
- UYUXSRADSPPKRZ-SKNVOMKLSA-N D-glucurono-6,3-lactone Chemical class O=C[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@H]1O UYUXSRADSPPKRZ-SKNVOMKLSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 208000009182 Parasitemia Diseases 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000009545 invasion Effects 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 239000012452 mother liquor Substances 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 239000012279 sodium borohydride Substances 0.000 description 6
- 229910000033 sodium borohydride Inorganic materials 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 238000005903 acid hydrolysis reaction Methods 0.000 description 5
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000003038 endothelium Anatomy 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 4
- 241000223960 Plasmodium falciparum Species 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 210000004088 microvessel Anatomy 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 3
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 3
- 206010062506 Heparin-induced thrombocytopenia Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000872931 Myoporum sandwicense Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- 239000003114 blood coagulation factor Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229940087051 fragmin Drugs 0.000 description 3
- 229960002442 glucosamine Drugs 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 150000002497 iodine compounds Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000003055 low molecular weight heparin Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- OVCDSSHSILBFBN-UHFFFAOYSA-N Amodiaquine Chemical compound C1=C(O)C(CN(CC)CC)=CC(NC=2C3=CC=C(Cl)C=C3N=CC=2)=C1 OVCDSSHSILBFBN-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- PRDZVHCOEWJPOB-IVMDWMLBSA-N N-sulfo-D-glucosamine Chemical compound OC[C@H]1OC(O)[C@H](NS(O)(=O)=O)[C@@H](O)[C@@H]1O PRDZVHCOEWJPOB-IVMDWMLBSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- PJSFRIWCGOHTNF-UHFFFAOYSA-N Sulphormetoxin Chemical compound COC1=NC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1OC PJSFRIWCGOHTNF-UHFFFAOYSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- 229960001444 amodiaquine Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- 238000002845 discoloration Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000002628 heparin derivative Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229940127215 low-molecular weight heparin Drugs 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- UCRHFBCYFMIWHC-UHFFFAOYSA-N piperaquine Chemical compound ClC1=CC=C2C(N3CCN(CC3)CCCN3CCN(CC3)C=3C4=CC=C(C=C4N=CC=3)Cl)=CC=NC2=C1 UCRHFBCYFMIWHC-UHFFFAOYSA-N 0.000 description 2
- 229950006717 piperaquine Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 229960004673 sulfadoxine Drugs 0.000 description 2
- 230000019635 sulfation Effects 0.000 description 2
- 238000005670 sulfation reaction Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 description 1
- LCTORNIWLGOBPB-GASJEMHNSA-N (3r,4s,5s,6r)-2-amino-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound NC1(O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O LCTORNIWLGOBPB-GASJEMHNSA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- IOTAOYHKWICOBK-UHFFFAOYSA-N 1-[amino-(4-chloroanilino)methylidene]-2-propan-2-ylguanidine;3-[4-(4-chlorophenyl)cyclohexyl]-4-hydroxynaphthalene-1,2-dione;hydrochloride Chemical compound Cl.CC(C)N=C(N)\N=C(/N)NC1=CC=C(Cl)C=C1.O=C1C(=O)C2=CC=CC=C2C(O)=C1C(CC1)CCC1C1=CC=C(Cl)C=C1 IOTAOYHKWICOBK-UHFFFAOYSA-N 0.000 description 1
- GJOHLWZHWQUKAU-UHFFFAOYSA-N 5-azaniumylpentan-2-yl-(6-methoxyquinolin-8-yl)azanium;dihydrogen phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.N1=CC=CC2=CC(OC)=CC(NC(C)CCCN)=C21 GJOHLWZHWQUKAU-UHFFFAOYSA-N 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
- 208000002476 Falciparum Malaria Diseases 0.000 description 1
- FZHXIRIBWMQPQF-UHFFFAOYSA-N Glc-NH2 Natural products O=CC(N)C(O)C(O)C(O)CO FZHXIRIBWMQPQF-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010018985 Haemorrhage intracranial Diseases 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 1
- 102000002397 Kinins Human genes 0.000 description 1
- 108010093008 Kinins Proteins 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010035500 Plasmodium falciparum infection Diseases 0.000 description 1
- 201000011336 Plasmodium falciparum malaria Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 229940122055 Serine protease inhibitor Drugs 0.000 description 1
- 101710102218 Serine protease inhibitor Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002535 acidifier Substances 0.000 description 1
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960000981 artemether Drugs 0.000 description 1
- 229960002521 artenimol Drugs 0.000 description 1
- BJDCWCLMFKKGEE-ISOSDAIHSA-N artenimol Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-ISOSDAIHSA-N 0.000 description 1
- 229940114027 atovaquone / proguanil Drugs 0.000 description 1
- 238000013142 basic testing Methods 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000003352 cell adhesion assay Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 229960000860 dapsone Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229930016266 dihydroartemisinin Natural products 0.000 description 1
- SXYIRMFQILZOAM-HVNFFKDJSA-N dihydroartemisinin methyl ether Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@@H](OC)O[C@H]4[C@]32OO[C@@]1(C)O4 SXYIRMFQILZOAM-HVNFFKDJSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 238000010949 in-process test method Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- ICIWUVCWSCSTAQ-UHFFFAOYSA-N iodic acid Chemical class OI(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-N 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- DYLGFOYVTXJFJP-MYYYXRDXSA-N lumefantrine Chemical compound C12=CC(Cl)=CC=C2C=2C(C(O)CN(CCCC)CCCC)=CC(Cl)=CC=2\C1=C/C1=CC=C(Cl)C=C1 DYLGFOYVTXJFJP-MYYYXRDXSA-N 0.000 description 1
- 229960004985 lumefantrine Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960001962 mefloquine Drugs 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 150000002772 monosaccharides Chemical group 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960005179 primaquine Drugs 0.000 description 1
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 1
- 229960000611 pyrimethamine Drugs 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 238000011946 reduction process Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000001563 schizont Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 229950008422 sevuparin sodium Drugs 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
- C08B37/0078—Degradation products
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Materials Engineering (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/SE2011/051538 WO2013095215A1 (en) | 2011-12-19 | 2011-12-19 | Low anticoagulant heparins |
| SEPCT/SE2011/051538 | 2011-12-19 | ||
| PCT/SE2012/051428 WO2013095276A1 (en) | 2011-12-19 | 2012-12-19 | Low anticoagulant heparins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018112162A Division JP2018154848A (ja) | 2011-12-19 | 2018-06-12 | 低抗凝固剤ヘパリン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015500387A JP2015500387A (ja) | 2015-01-05 |
| JP2015500387A5 JP2015500387A5 (enExample) | 2016-12-01 |
| JP6703806B2 true JP6703806B2 (ja) | 2020-06-03 |
Family
ID=48668926
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014547145A Active JP6703806B2 (ja) | 2011-12-19 | 2012-12-19 | 低抗凝固剤ヘパリン |
| JP2018112162A Pending JP2018154848A (ja) | 2011-12-19 | 2018-06-12 | 低抗凝固剤ヘパリン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018112162A Pending JP2018154848A (ja) | 2011-12-19 | 2018-06-12 | 低抗凝固剤ヘパリン |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US9480702B2 (enExample) |
| EP (2) | EP2794666B1 (enExample) |
| JP (2) | JP6703806B2 (enExample) |
| CN (1) | CN104053675B (enExample) |
| AU (1) | AU2012354226B2 (enExample) |
| BR (1) | BR112014014673B1 (enExample) |
| CA (2) | CA2856918C (enExample) |
| CY (2) | CY1120197T1 (enExample) |
| DK (2) | DK2794667T3 (enExample) |
| ES (2) | ES2669055T3 (enExample) |
| HR (2) | HRP20180725T1 (enExample) |
| HU (2) | HUE037555T2 (enExample) |
| IL (1) | IL232903A (enExample) |
| IN (1) | IN2014MN01056A (enExample) |
| MX (1) | MX358439B (enExample) |
| MY (1) | MY170069A (enExample) |
| NO (2) | NO2794667T3 (enExample) |
| PH (1) | PH12014501387A1 (enExample) |
| PL (2) | PL2794666T3 (enExample) |
| PT (2) | PT2794667T (enExample) |
| RS (2) | RS57213B1 (enExample) |
| SI (2) | SI2794667T1 (enExample) |
| SM (2) | SMT201800217T1 (enExample) |
| TN (2) | TN2014000237A1 (enExample) |
| WO (3) | WO2013095215A1 (enExample) |
| ZA (1) | ZA201403654B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6543467B2 (ja) | 2011-12-19 | 2019-07-10 | ディラホア アクチエボラゲット | 二糖繰り返し単位を含んでいる非抗凝固グリコサミノグリカンおよびそれらの医療用途 |
| WO2013095215A1 (en) | 2011-12-19 | 2013-06-27 | Dilaforette Ab | Low anticoagulant heparins |
| GB2515315A (en) | 2013-06-19 | 2014-12-24 | Dilafor Ab | New Processes |
| US20170049862A1 (en) * | 2014-04-30 | 2017-02-23 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for treating vaso-occlusive crisis |
| EP2965764A1 (en) * | 2014-07-11 | 2016-01-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating vaso-occlusive crisis |
| CN105504097B (zh) * | 2015-12-30 | 2018-07-03 | 深圳市海普瑞药业集团股份有限公司 | 一种硫酸化肝素寡糖及其制备方法和应用 |
| CN108424474B (zh) * | 2017-02-15 | 2023-07-25 | 清华大学 | 去抗凝肝素衍生物及其用于炎症性肠病的治疗 |
| EP3773770B1 (en) * | 2018-04-13 | 2023-11-29 | University of Virginia Patent Foundation | Compositions and methods for preparing and using non-immunogenic fast annealing microporous annealed particle hydrogels |
| CN109481692A (zh) * | 2018-11-30 | 2019-03-19 | 东南大学 | 一种青蒿琥酯肝素衍生物及其药物组合物和应用 |
| WO2023192344A1 (en) * | 2022-03-29 | 2023-10-05 | The Penn State Research Foundation | Device and method for accelerating and guiding vascularization |
| WO2023215594A1 (en) | 2022-05-05 | 2023-11-09 | Venture Health Studio, Llc | Magnetic power distribution assembly |
| EP4536248A1 (en) * | 2022-06-06 | 2025-04-16 | IHP Therapeutics Inc. | Chemically modified heparin |
| CN115448994B (zh) * | 2022-09-28 | 2023-08-01 | 山东大学 | 一种可中和抗凝低分子量肝素及其制备方法和应用 |
| US12059430B2 (en) | 2022-09-29 | 2024-08-13 | Adora Animal Health Corporation | Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions |
| GB2625581A (en) | 2022-12-21 | 2024-06-26 | Modus Therapeutics Ab | New medical use |
| WO2024170746A1 (en) | 2023-02-17 | 2024-08-22 | Modus Therapeutics Ab | New medical use of sevuparin in the treatment of endotoxemia |
| GB2627263A (en) * | 2023-02-17 | 2024-08-21 | Modus Therapeutics Ab | New medical use |
| CN116854838A (zh) * | 2023-06-30 | 2023-10-10 | 重庆望业药物研究有限公司 | 低分子多糖及其制备方法与应用 |
| GB202407366D0 (en) * | 2024-05-23 | 2024-07-10 | Glycos Biomedical Ltd | Preparation of medium molecular weight heparin |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1136620A (en) | 1979-01-08 | 1982-11-30 | Ulf P.F. Lindahl | Heparin fragments having selective anticoagulation activity |
| FR2614026B1 (fr) | 1987-04-16 | 1992-04-17 | Sanofi Sa | Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques |
| DE68906345T2 (de) * | 1988-10-07 | 1993-10-28 | Hoechst Ag | Antimalariazusammenstellungen, gebrauchmachend von Quinidin, Artemisinin und ihren Derivaten. |
| SE9002550D0 (sv) | 1990-08-01 | 1990-08-01 | Kabivitrum Ab | Heparinfragment |
| SE9003181D0 (sv) | 1990-10-04 | 1990-10-04 | Kabivitrum Ab | Use of heparin fraction |
| US5250519A (en) * | 1991-03-29 | 1993-10-05 | Glycomed Incorporated | Non-anticoagulant heparin derivatives |
| US5280016A (en) * | 1991-03-29 | 1994-01-18 | Glycomed Incorporated | Non-anticoagulant heparin derivatives |
| JPH0532703A (ja) * | 1991-07-26 | 1993-02-09 | Terumo Corp | 低分子量ヘパリン誘導体の製造法 |
| AU5442594A (en) | 1992-10-13 | 1994-05-09 | Virginia Commonwealth University | Use of non-anticoagulant heparin for treating ischemia/reperfusion injury |
| US5527785A (en) * | 1993-05-14 | 1996-06-18 | The Regents Of The University Of California | Selectin receptor modulating compositions |
| ATE224918T1 (de) * | 1995-03-31 | 2002-10-15 | Hamilton Civic Hospitals Res | Zusammensetzung zur hemmung der thromboseentstehung |
| US5993810A (en) | 1996-03-15 | 1999-11-30 | Lebovitz; Shamir Israel | Method of softening or ripening the cervix of a female mammal using collagenase |
| US5767269A (en) | 1996-10-01 | 1998-06-16 | Hamilton Civic Hospitals Research Development Inc. | Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics |
| JP4203611B2 (ja) | 1996-10-15 | 2009-01-07 | 生化学工業株式会社 | 子宮頸管熟化剤 |
| GB9711443D0 (en) | 1997-06-03 | 1997-07-30 | Leo Pharm Prod Ltd | Chemical suppositions |
| WO1999026984A1 (fr) * | 1997-11-20 | 1999-06-03 | Ikuo Yamashina | Modification de l'heparine de faible masse moleculaire et remede contre l'ulcere de la peau |
| US6596705B1 (en) | 1998-02-09 | 2003-07-22 | The Regents Of The University Of California | Inhibition of L-selectin and P-selection mediated binding using heparin |
| US6498246B1 (en) | 1998-02-26 | 2002-12-24 | Seikagaku Corporation | Glycosaminoglycan derivatives and processes for preparing same |
| US6028061A (en) * | 1998-06-18 | 2000-02-22 | Children's Medical Center Corp | Angiogenesis inhibitors and use thereof |
| KR20010030803A (ko) * | 1998-07-31 | 2001-04-16 | 야마야 와따루 | 신규 글리코사미노글리칸 및 이를 함유하는 의약 조성물 |
| HUP0201712A3 (en) * | 1999-06-30 | 2003-03-28 | Weitz Jeffrey I Ancaster | Clot associated coagulation factors inhibiting heparin compositions |
| JP4897991B2 (ja) * | 1999-07-23 | 2012-03-14 | ラボラトリオス ファルマセウティコス ロビ ソシエダッド アノニマ | 超低分子量ヘパリン組成物 |
| IT1316986B1 (it) | 2000-01-25 | 2003-05-26 | Sigma Tau Ind Farmaceuti | Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica. |
| JP4585072B2 (ja) * | 2000-02-29 | 2010-11-24 | 扶桑薬品工業株式会社 | ヘパリン解重合法、解重合ヘパリン、その誘導体および医薬組成物 |
| PT1319183E (pt) * | 2000-09-12 | 2009-06-29 | Massachusetts Inst Technology | Métodos e produtos relacionados a heparina de baixo peso molecular |
| SE521676C2 (sv) | 2002-01-02 | 2003-11-25 | Dilafor Ab | Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet |
| EP1542704A1 (en) | 2002-04-18 | 2005-06-22 | Stephen H. Embury | Method and composition for preventing pain in sickle cell patients |
| US8071569B2 (en) * | 2002-09-20 | 2011-12-06 | Mousa Shaker A | Oxidized heparin fractions and their use in inhibiting angiogenesis |
| EP1582531A1 (en) | 2004-03-24 | 2005-10-05 | Aventis Pharma S.A. | Process for oxidizing unfractionated heparins and detecting presence or absence of glycoserine in heparin and heparin products |
| JP5154924B2 (ja) * | 2004-05-11 | 2013-02-27 | エガレット エイ／エス | ジェランガムを含む膨張可能な投与形態 |
| US20060040896A1 (en) * | 2004-08-18 | 2006-02-23 | Paringenix, Inc. | Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity |
| US7741311B2 (en) * | 2005-01-03 | 2010-06-22 | Shaker Mousa | Composition and method for treating occlusive vascular diseases, nerve regeneration, and wound healing |
| US20070021378A1 (en) * | 2005-07-22 | 2007-01-25 | The Regents Of The University Of California | Heparin compositions and selectin inhibition |
| CA2616230A1 (en) * | 2005-07-22 | 2007-02-01 | Trf Pharma, Inc. | Method for treating sickle cell disease and sickle cell disease sequelae |
| EP2404939A3 (en) * | 2006-05-25 | 2012-03-21 | Momenta Pharmaceuticals, Inc. | Low molecular weight heparin composition and uses thereof |
| WO2009007224A1 (en) * | 2007-07-10 | 2009-01-15 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Low molecular weight heparin derivatives having neuroprotective activity |
| EP2205642B1 (en) * | 2007-11-02 | 2016-01-27 | Momenta Pharmaceuticals, Inc. | Non-anticoagulant polysaccharide compositions |
| US8569262B2 (en) | 2007-11-02 | 2013-10-29 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
| US8592393B2 (en) * | 2007-11-02 | 2013-11-26 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
| WO2009073184A1 (en) | 2007-12-03 | 2009-06-11 | Florida State University Research Foundation, Inc. | Compositions for inducing labor and associated methods |
| BRPI0909849A2 (pt) * | 2008-04-04 | 2015-10-06 | Univ Utah Res Found | éteres semi-sintéticos de glicosaminoglicosanos e métodos para fazê-los e usá-los |
| US20110206770A1 (en) * | 2008-07-25 | 2011-08-25 | Alphapharm Pty. Ltd. | Atovaquone with a particle size diameter range (d90) of greater than 3 microns to about 10 microns |
| DK2419736T3 (da) * | 2009-04-16 | 2014-04-22 | Momenta Pharmaceuticals Inc | Fremgangsmåder til vurdering af aktivitet af en polysaccharidsammensætning |
| AU2010268756A1 (en) * | 2009-06-30 | 2012-01-19 | The Walter And Eliza Hall Institute Of Medical Research | Sulfated polysaccharides having antiplasmodial activity and methods and products for identifying antiplasmodial activity |
| WO2013095215A1 (en) | 2011-12-19 | 2013-06-27 | Dilaforette Ab | Low anticoagulant heparins |
| JP6543467B2 (ja) | 2011-12-19 | 2019-07-10 | ディラホア アクチエボラゲット | 二糖繰り返し単位を含んでいる非抗凝固グリコサミノグリカンおよびそれらの医療用途 |
| MX2014011505A (es) | 2012-03-26 | 2014-12-05 | Dilafor Ab | Terapias para inducir el parto. |
| CN104244957B (zh) | 2012-03-26 | 2017-11-17 | 迪乐方有限责任公司 | 用于治疗分娩停止的方法 |
-
2011
- 2011-12-19 WO PCT/SE2011/051538 patent/WO2013095215A1/en not_active Ceased
-
2012
- 2012-12-19 CA CA2856918A patent/CA2856918C/en not_active Expired - Fee Related
- 2012-12-19 IN IN1056MUN2014 patent/IN2014MN01056A/en unknown
- 2012-12-19 HR HRP20180725TT patent/HRP20180725T1/hr unknown
- 2012-12-19 JP JP2014547145A patent/JP6703806B2/ja active Active
- 2012-12-19 DK DK12860938.5T patent/DK2794667T3/en active
- 2012-12-19 BR BR112014014673-0A patent/BR112014014673B1/pt active IP Right Grant
- 2012-12-19 SI SI201231283T patent/SI2794667T1/en unknown
- 2012-12-19 RS RS20180552A patent/RS57213B1/sr unknown
- 2012-12-19 NO NO12860938A patent/NO2794667T3/no unknown
- 2012-12-19 PL PL12859384T patent/PL2794666T3/pl unknown
- 2012-12-19 AU AU2012354226A patent/AU2012354226B2/en active Active
- 2012-12-19 SI SI201231282T patent/SI2794666T1/en unknown
- 2012-12-19 NO NO12859384A patent/NO2794666T3/no unknown
- 2012-12-19 US US14/366,603 patent/US9480702B2/en active Active
- 2012-12-19 HU HUE12860938A patent/HUE037555T2/hu unknown
- 2012-12-19 RS RS20180574A patent/RS57214B1/sr unknown
- 2012-12-19 ES ES12860938.5T patent/ES2669055T3/es active Active
- 2012-12-19 PL PL12860938T patent/PL2794667T3/pl unknown
- 2012-12-19 CN CN201280062042.7A patent/CN104053675B/zh active Active
- 2012-12-19 SM SM20180217T patent/SMT201800217T1/it unknown
- 2012-12-19 HU HUE12859384A patent/HUE037554T2/hu unknown
- 2012-12-19 PT PT128609385T patent/PT2794667T/pt unknown
- 2012-12-19 DK DK12859384.5T patent/DK2794666T3/en active
- 2012-12-19 WO PCT/SE2012/051429 patent/WO2013095277A1/en not_active Ceased
- 2012-12-19 EP EP12859384.5A patent/EP2794666B1/en active Active
- 2012-12-19 CA CA2856477A patent/CA2856477C/en active Active
- 2012-12-19 US US14/366,570 patent/US9480701B2/en active Active
- 2012-12-19 MX MX2014006956A patent/MX358439B/es active IP Right Grant
- 2012-12-19 HR HRP20180726TT patent/HRP20180726T1/hr unknown
- 2012-12-19 EP EP12860938.5A patent/EP2794667B1/en active Active
- 2012-12-19 MY MYPI2014001796A patent/MY170069A/en unknown
- 2012-12-19 SM SM20180218T patent/SMT201800218T1/it unknown
- 2012-12-19 WO PCT/SE2012/051428 patent/WO2013095276A1/en not_active Ceased
- 2012-12-19 PT PT128593845T patent/PT2794666T/pt unknown
- 2012-12-19 ES ES12859384.5T patent/ES2668273T3/es active Active
-
2014
- 2014-05-20 ZA ZA2014/03654A patent/ZA201403654B/en unknown
- 2014-05-29 TN TNP2014000237A patent/TN2014000237A1/en unknown
- 2014-05-29 TN TNP2014000236A patent/TN2014000236A1/en unknown
- 2014-06-01 IL IL232903A patent/IL232903A/en active IP Right Grant
- 2014-06-18 PH PH12014501387A patent/PH12014501387A1/en unknown
-
2018
- 2018-05-10 CY CY20181100483T patent/CY1120197T1/el unknown
- 2018-05-10 CY CY20181100482T patent/CY1120194T1/el unknown
- 2018-06-12 JP JP2018112162A patent/JP2018154848A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6703806B2 (ja) | 低抗凝固剤ヘパリン | |
| FR2614026A1 (fr) | Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques | |
| AU2012354229B2 (en) | Non anti-coagulative glycosaminoglycans comprising repeating disaccharide unit and their medical use | |
| JP2005505537A (ja) | 低分子量ヘパリンと低分子量デルマタン硫酸とを含む抗血栓組成物 | |
| HK1200471B (en) | Low anticoagulant heparins | |
| NZ625096B2 (en) | Low anticoagulant heparins | |
| HK1199893B (en) | Use of chemically modified heparin derivates in sickle cell disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151216 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20151216 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161012 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20161012 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20161020 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170110 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170407 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170613 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170912 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171031 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180131 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20180213 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190524 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190528 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190712 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200128 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200511 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6703806 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |